CAR-T therapy's cost per QALY is approximately $100,000, with consistent results across PSM, STM, and DES models. DES uniquely incorporates wait time, significantly affecting CAR-T's ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows. However, ...

A new study claims a certified registered nurse anesthetist working as the sole anesthesia provider is the most cost-effective model of anesthesia delivery and doesn’t impact care quality, according ...

Treatment with abelacimab could result in potential cost-savings of $50,000 over a lifetime per patient basis and higher quality-adjusted life years in atrial fibrillation patients at a high risk of ...

Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is partly ...

Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine. Objective: Migraine is a debilitating chronic disorder requiring multifaceted ...

A hypothetical cohort of women, assumed to be initially free of osteoporosis-related bone fractures, is followed on an annual basis for 25 years. Women in the cohort face risks for three important ...

Durvalumab cost-effectiveness in limited-stage small cell lung cancer failed to meet US value thresholds despite longer ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the publication of a novel health economic model in the Journal of Medical Economics, funded by Bayer, analyzing cost effectiveness and ...

Background. Clostridium difficile infection (CDI) is the most commonly recognized cause of recurrent diarrhea. Bezlotoxumab, administered concurrently with antibiotics directed against C. difficile ...